IOME BIO

📍 Strasbourg, France🗓 Founded 2020👥 7 employees💰 Last funded Feb 2021
Biotechnology Research🌐 iomebio.com
Website LinkedIn
Cancer continues to be a leading cause of disability and early mortality worldwide. Immune checkpoint blockade with PD/L-1 therapies such as Keytruda and Opdivo can induce complete and durable clinical responses in multiple tumors, a breakthrough in cancer treatment over the last decade. However, only around 20% of patients respond and many trials have failed Many R&D programs in multiple companies are attempting to improve the clinical efficacy of PD/L-1 therapies, but no solution is yet approved. Most of these approaches target T-cells or the tumour microenvironment. Patients with healthier microbiomes respond better and therefore some companies are developing live biotherapeutics to enhance the microbiome, with initially promising clinical data. Iome-Bio offers a differentiated approach through a targeted mode of action downstream of the microbiome’s action, enabling amplification of the signal with first in class monoclonal antibodies.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in IOME BIO?
IOME BIO has 1 investors on record on gritt.io, including 1 early-stage backers.
When did IOME BIO last raise funding?
The most recent investment in IOME BIO recorded on gritt.io was in February 2021.
When was IOME BIO founded?
IOME BIO was founded in 2020.
What industry is IOME BIO in?
IOME BIO operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is IOME BIO based?
IOME BIO is headquartered in Strasbourg, France.